Top Story

VOYAGE 1: Guselkumab yields encouraging outcomes in plaque psoriasis

September 19, 2017

At 100 weeks, more than 80% of patients with moderate to severe plaque psoriasis showed improvement after treatment with guselkumab, according to findings presented at the 26th European Academy of Dermatology and Venereology Congress.

The data were from the 2-year, open-label follow-up of the VOYAGE 1 trial. The cohort of patients treated with guselkumab (Tremfya, Janssen), an anti-interleukin-23 monoclonal antibody, included patients who had previously been treated with adalimumab (Humira, AbbVie).

Meeting NewsPerspective

AAP offers guidelines to reduce risks linked to body art in teens

September 18, 2017
CHICAGO — Parents of teenagers considering tattoos, piercings or scarification — cutting, burning or branding the skin — are encouraged to inform their…
Meeting News

Adalimumab biosimilar safety, efficacy matches Humira through 51 weeks

September 18, 2017
A biosimilar of adalimumab was associated with similar safety and efficacy outcomes compared with Humira in a cohort of patients with chronic plaque psoriasis, according…
In the Journals

Topical fluorouracil 5% cream fails to improve photoaging

September 15, 2017
Patients treated with a course of fluorouracil 5% cream experienced no significant improvements in parameters associated with photodamage caused by long-term ultraviolet…
More Headlines »

Preventing Medical Errors for Clinical Health Professionals

No commercial support for this activity.

This educational monograph addresses the identification, reporting, monitoring and reduction of medical error. It is…
More »
GI Bookshelf

Chapter 40: Progressive Ascites In a Patient From Sierra Leone

From Complicated Cases in GI
More »
Resource Centers
Meeting News

VIDEO: Pembrolizumab improves overall survival in nonsmall cell lung cancer

May 5, 2017
More »